Kairos Pharma, LTD.
Close on Oct 19, 2026
- Market cap
- $12.21M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Kairos Pharma has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Kairos Pharma filed with the SEC
Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Announces 1-for-7 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Material agreement · Other events · EX-99.1 to Form 8-K
Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105
Other events · EX-99.1 to Form 8-K
Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines
Material agreement · Other events · EX-99.1 to Form 8-K
Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics
Other events · EX-99.1 to Form 8-K
Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025
Material agreement · Other events · EX-99.1 to Form 8-K
Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
Other events · EX-99.1 to Form 8-K
Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer
Other events · EX-99.1 to Form 8-K
Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
Other events · EX-99.1 to Form 8-K
Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society
Other events · EX-99.1 to Form 8-K
Pharma Ltd. Provides Letter to Stockholders
Other events · EX-99.1 to Form 8-K
Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential
Other events · EX-99.1 to Form 8-K
Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13 th AACR-JCA Joint Conference Supports the Compound’s
Other events · EX-99.1 to Form 8-K
Pharma Approved to Dual List on Upstream
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Pharma Enters Agreement with PreCheck Health Services
Material agreement · Other events · EX-99.1 to Form 8-K
Pharma Closing of $6.2 Million Initial Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K